Microangiopathic hemolytic anemia - Revision history

ClaireLewis at 04:51, 1 October 2019

2019-10-01T04:51:05Z

← Revisión anterior		Revisión del 04:51 1 oct 2019
Línea 5:		Línea 5:
	==Clinical Features==		==Clinical Features==
	*Clinical features + heme labs with red blood cell fragments or schistocytes.<ref name="guidelines">Scully. Marie et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 Aug;158(3):323-35. [http://www.bcshguidelines.com/documents/BJH_TTP_Guideline_0512.pdf PDF]</ref>		*Clinical features + heme labs with red blood cell fragments or schistocytes.<ref name="guidelines">Scully. Marie et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 Aug;158(3):323-35. [http://www.bcshguidelines.com/documents/BJH_TTP_Guideline_0512.pdf PDF]</ref>
	*May have bleeding and thrombosis		*May have [[hemorrhage\|bleeding]] and [[thromboembolism\|thrombosis]]
			*Signs and symptoms of [[anemia]] (fatigue, pallor, palpitations, etc.)
			*[[Jaundice]] and scleral icterus
			*Signs/symptoms of underlying disease process

	==Differential Diagnosis==		==Differential Diagnosis==

2017-10-08T17:34:32Z

← Revisión anterior		Revisión del 17:34 8 oct 2017
Línea 4:		Línea 4:

	==Clinical Features==		==Clinical Features==
	*Clinical features + heme labs with red blood cell fragments or schistocytes.<ref name="guidelines">Scully. Marie et al. Guidelines on the diagnosis and management of		*Clinical features + heme labs with red blood cell fragments or schistocytes.<ref name="guidelines">Scully. Marie et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 Aug;158(3):323-35. [http://www.bcshguidelines.com/documents/BJH_TTP_Guideline_0512.pdf PDF]</ref>
	thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 Aug;158(3):323-35. [http://www.bcshguidelines.com/documents/BJH_TTP_Guideline_0512.pdf PDF]</ref>
	*May have bleeding and thrombosis		*May have bleeding and thrombosis

2016-07-24T02:03:03Z

Text replacement - "==Diagnosis==" to "==Evaluation=="

← Revisión anterior		Revisión del 02:03 24 jul 2016
Línea 11:		Línea 11:
	{{Hemolytic anemia DDX}}		{{Hemolytic anemia DDX}}

	==~~Diagnosis~~==		==Evaluation==
	*Peripheral smear, hemoglobin, platelets, PT/INR, PTT, fibrinogen, FDPs, D-dimer, haptoglobin, LDH, bilirubin		*Peripheral smear, hemoglobin, platelets, PT/INR, PTT, fibrinogen, FDPs, D-dimer, haptoglobin, LDH, bilirubin
	**Schistocytes (aka Helmet cells) secondary to fragmentation hemolysis classic finding on peripheral smear		**Schistocytes (aka Helmet cells) secondary to fragmentation hemolysis classic finding on peripheral smear

2016-06-03T16:32:42Z

← Revisión anterior	Revisión del 16:32 3 jun 2016
(Sin diferencias)

2016-06-03T16:32:25Z

Background

← Revisión anterior		Revisión del 16:32 3 jun 2016
Línea 1:		Línea 1:
	==Background==		==Background==
			*Abbreviation: MAHA
	*A variety of conditions that result in damaged endothelium of small vessels causing platelet aggregation and fibrin deposition which leads to shearing forces within these small vessels causing an intravascular fragmentation hemolysis		*A variety of conditions that result in damaged endothelium of small vessels causing platelet aggregation and fibrin deposition which leads to shearing forces within these small vessels causing an intravascular fragmentation hemolysis

2016-06-03T16:32:00Z

Management

2015-08-04T12:12:16Z

2015-08-04T12:11:46Z

2015-06-29T13:07:56Z

Differential Diagnosis

← Revisión anterior		Revisión del 13:07 29 jun 2015
Línea 8:		Línea 8:

	==Differential Diagnosis==		==Differential Diagnosis==
	*Most common causes: [[DIC]], [[TTP]], [[HUS]]
	*Other medical causes: [[malignant hypertension]], [[HELLP]], [[Antiphospholipid Syndrome (APS)]], [[scleroderma]], [[Paroxysmal Nocturnal Hemoglobinuria (PNH)]], malignancy, renal allograft rejection, vasculitides like [[polyarteritis nodosa]] and [[Wegener's granulomatosis]]
	*Drugs: chemotherapy; [[Clopidogrel]] (Plavix) associated with [[TTP]]
	*Nonvascular causes: prosthetic valve (more common w/ mechanical, more common at aortic valve), [[LVAD]], [[TIPS]], coil embolization, patched AV shunt, [[AVM]]

	{{Hemolytic anemia DDX}}		{{Hemolytic anemia DDX}}

2015-06-29T13:06:59Z

Background

← Revisión anterior		Revisión del 13:06 29 jun 2015
Línea 1:		Línea 1:
	==Background==		==Background==
	~~'''Microangiopathic hemolytic anemia (MAHA)''' =~~ variety of conditions that result in damaged endothelium of small vessels causing platelet aggregation and fibrin deposition which leads to shearing forces within these small vessels causing an intravascular fragmentation hemolysis		*A variety of conditions that result in damaged endothelium of small vessels causing platelet aggregation and fibrin deposition which leads to shearing forces within these small vessels causing an intravascular fragmentation hemolysis

	==Clinical Features==		==Clinical Features==

← Revisión anterior		Revisión del 12:12 4 ago 2015
Línea 28:		Línea 28:
	==See Also==		==See Also==
	*[[Anemia]]		*[[Anemia]]
	*[[Malignant hypertension]], [[HELLP]], [[Antiphospholipid Syndrome (APS)]], [[Paroxysmal Nocturnal Hemoglobinuria (PNH)]]

	==References==		==References==
	<references/>		<references/>
	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

← Revisión anterior		Revisión del 12:11 4 ago 2015
Línea 27:		Línea 27:

	==See Also==		==See Also==
	*[[~~DIC]]~~		*[[Anemia]]
	*[[TTP]]
	*[[HUS]]
	*[[Malignant hypertension]], [[HELLP]], [[Antiphospholipid Syndrome (APS)]], [[Paroxysmal Nocturnal Hemoglobinuria (PNH)]]		*[[Malignant hypertension]], [[HELLP]], [[Antiphospholipid Syndrome (APS)]], [[Paroxysmal Nocturnal Hemoglobinuria (PNH)]]
	*[[HIT]]

	==References==		==References==
	<references/>		<references/>
	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]